Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

45.14 -0.55 (-1.20%)
Delayed Quote Updated: 10:42 AM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Alkermes Celebrates National Women's Health Week by Reminding You Why Regular Cancer Screenings Are Vital
SOURCE: Alkermes 
Via 3BL Media
News headline image
Alkermes to Highlight Data Related to Psychiatry Portfolio at Upcoming Scientific Conferences During Mental Health Awareness Month
SOURCE: Alkermes 
Via 3BL Media
News headline image
Looking Into Alkermes's Return On Capital Employed ↗
Benzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q1 sales of $278.55 million. Earnings fell to a loss of $35.90 million, resulting in a 4212.6% decrease from last quarter. 
Via Benzinga
News headline image
38 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Vivakor, Inc. (NASDAQ: VIVK) gained 154% to $4.3550 after the company announced it has signed a 10-year contract with Hot Oil Transport with a potential value of... 
Via Benzinga
News headline image
Recap: Alkermes Q1 Earnings ↗
Alkermes (NASDAQ:ALKS) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Expert Ratings for Alkermes ↗
Alkermes (NASDAQ:ALKS) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
61 Biggest Movers From Yesterday ↗
Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed a 10-year contract with Hot Oil Transport with... 
Via Benzinga
News headline image
LGBTQ+ People Are More Likely to Experience a Mental Health Condition
SOURCE: Alkermes 
Via 3BL Media
Topics LGBTQ
News headline image
Recap: Alkermes Q4 Earnings ↗
  Alkermes (NASDAQ:ALKS) reported its Q4 earnings results on Wednesday, February 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Earnings Scheduled For February 16, 2022 ↗
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on revenue of $331.16 million. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Alkermes's Earnings Outlook ↗
Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will... 
Via Benzinga
News headline image
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More ↗
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
Via Benzinga
News headline image
Alkermes Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗
Alkermes (NASDAQ:ALKS) will host a conference call at 08:00 AM ET on April 27, 2022, to discuss Q1 2022 earnings results. How to Attend Alkermes (ALKS) Conference Call Follow this link to access the... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Alkermes Starts Arbitration Related to NanoCrystal Tech Agreements With Janssen ↗
 
Via Benzinga
News headline image
This Biotech Company Is Landing Ketamine-Assisted Therapy In England's Capital ↗
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. As it pushes ahead with expansion into the United States,... 
Via Benzinga
News headline image
This Ketamine-Assisted Therapy Company Is Developing New Ways To Treat Alcohol Addiction ↗
Picture credit: Martin Sanchez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Nektar Therapeutics Loses Half Its Value As Bristol Myers-Paired Melanoma Test Flops ↗
Sentiment was low heading into the study and analysts aren't hopeful for other tests. 
Via Investor's Business Daily
Rising Number of Mental Health Disorders Fuel Advancing Initiatives to Reduce Psychiatric and Neurological Conditions
Palm Beach, FL –– March 8, 2022 – FinancialNewsMedia.com News Commentary – According to a report from Grand View Research “High unmet medical needs and government initiatives to reduce the psychiatric... 
Via FinancialNewsMedia
Topics Economy
News headline image
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
News headline image
The Ruble Is Rubble ↗
MSCI says Russian companies are 
Via Talk Markets
News headline image
Alkermes' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer ↗
Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) variant... 
Via Benzinga
News headline image
Alkermes's Return On Capital Employed Overview ↗
According to Benzinga Pro, during Q4, Alkermes (NASDAQ:ALKS) earned $873.00 thousand, a 103.01% increase from the preceding quarter. Alkermes also posted a total of $324.46 million in sales, a 10.31%... 
Via Benzinga
News headline image
56 Biggest Movers From Yesterday ↗
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) gained 54.5% to close at $2.07 on Wednesday. Hookipa Pharma amended and restated collaboration and license agreement with Gilead... 
Via Benzinga
News headline image
Why Are Alkermes Shares Trading Higher Today? ↗
Alkermes plc's (NASDAQ: ALKS) Q4 sales increased 16% Y/Y to $324.5 million, beating the consensus of $308.69 million. Net sales of proprietary products were $178.9... 
Via Benzinga
News headline image
40 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) jumped 52.8% to $2.0478. Hookipa Pharma amended and restated collaboration and license agreement with Gilead Sciences for arenaviral... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following... 
Via Benzinga
News headline image
Earnings Preview For Alkermes ↗
Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.